Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DUPONT MERCK NEW PRESIDENT AND CEO LANDGRAF

Executive Summary

DUPONT MERCK NEW PRESIDENT AND CEO LANDGRAF is a 13-year DuPont veteran who will succeed Joseph Mollica, PhD, Dec. 1 when Mollica retires, the company announced Nov. 11. Kurt Landgraf, 47, has been in charge of sales, marketing and manufacturing for both the domestic and international sectors of DuPont Merck since the start-up of the joint venture in January 1991, when he was named exec VP. DuPont Merck has not appointed anyone to succeed Landgraf. The selection of Landgraf to succeed Mollica continues the dominance of former DuPont execs as the topsiders of the three- year-old joint venture ("The Pink Sheet" Feb. 11, 1991, T&G-7). Prior to the merger, Landgraf was director of the pharmaceuticals and imaging agents divisions and medical products department at DuPont; he also had a stint in DuPont's corporate plans department as a planning manager and was the pharmaceutical marketing director for Europe, the Middle East and Africa. Before joining DuPont in 1980, Landgraf worked at Upjohn and Johnson & Johnson. Mollica was also a former DuPont exec. The departure of Mollica, 53, is being characterized by DuPont Merck as a desire on his part to find an opportunity similar to the one he landed when the joint-venture was formed in mid-1990: he is hoping to "capitalize on his talents and abilities in creating and turning around organizations," the company said. During Mollica's tenure, sales doubled to over $1 bil. and DuPont Merck expanded its European presence, including the opening of subsidiaries in Italy and Spain; DuPont Merck markets its products in 80 countries.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS023586

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel